• Publications
  • Influence
Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase‐2
TLDR
Lumiracoxib is a highly selective COX‐2 inhibitor with anti‐inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
TLDR
Results of preclinical studies in rats studies suggest that robenacoxib has an attractive pharmacological profile for potential use in the intended target species, cats and dogs.
Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice.
TLDR
In vitro, ex vivo, and in vivo assays demonstrate that WYE-151650 is efficacious in mouse CIA despite JAK-3 selectivity, and question the need to broadly inhibit Jak-1,JAK-2, or Tyk-2-dependent cytokine pathways for efficacy.
Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo.
TLDR
C5aRAM and C5aRAD are novel, potent C 5a receptor antagonists devoid of agonist or proinflammatory activity with demonstrated efficacy in vitro and in vivo.
Characterization of CGS 8515 as a selective 5-lipoxygenase (5-LO) inhibitor.
TLDR
Ex vivo and in vivo studies with rats showed that CGS 8515 significantly inhibited A23187-induced formation of LTs in whole blood and in the lung, and significantly suppressed exudate volume and leukocyte migration in the carrageenan-induced pleurisy and sponge models in the rat.
Antimicrobial effectiveness of Locacorten-Vioform cream in Secondary infections of common dermatoses.
In a double-blind study involving 430 patients, Locacorten (0.02%)-Vioform (3%) cream was found to be highly effective in the treatment of dermatological conditions complicated by secondary bacterial
...
...